User profiles for P.L. Nghiemphu
 | Phioanh Leia Nghiemphuucla neurology/neuro-oncology Verified email at mednet.ucla.edu Cited by 12332 |
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
…, BJ O'Brien, NA Butowski, PL Nghiemphu… - Nature medicine, 2019 - nature.com
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
[HTML][HTML] Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly …
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly …
[HTML][HTML] Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
…, CJ Escovedo, W Chen, PL Nghiemphu… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT) is frequent
in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a …
in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a …
Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors
…, D Rohle, C Campos, C Grommes, PL Nghiemphu… - Cancer discovery, 2012 - AACR
Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs
through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR …
through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR …
Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma
JA Carrillo, A Lai, PL Nghiemphu… - American Journal …, 2012 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Both IDH1 mutation and MGMT promoter methylation are
associated with longer survival. We investigated the ability of imaging correlates to serve as …
associated with longer survival. We investigated the ability of imaging correlates to serve as …
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience
PL Nghiemphu, W Liu, Y Lee, T Than, C Graham… - Neurology, 2009 - AAN Enterprises
Objective: Bevacizumab has been shown to be effective in the treatment of recurrent
glioblastoma in combination with chemotherapy compared with historic controls but not in …
glioblastoma in combination with chemotherapy compared with historic controls but not in …
Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline
…, AB Lassman, J Morton, D Ney, PL Nghiemphu… - 2022 - academic.oup.com
Purpose To provide guidance to clinicians regarding therapy for diffuse astrocytic and
oligodendroglial tumors in adults. Methods ASCO and the Society for Neuro-Oncology convened …
oligodendroglial tumors in adults. Methods ASCO and the Society for Neuro-Oncology convened …
Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma
…, J Goldin, MS Brown, PL Nghiemphu… - American Journal …, 2011 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Currently it is difficult to predict tumor response to anti-angiogenic
therapy in individual patients. Our aim was to determine if ADC histogram analysis …
therapy in individual patients. Our aim was to determine if ADC histogram analysis …
Probabilistic radiographic atlas of glioblastoma phenotypes
BACKGROUND AND PURPOSE: Tumor location is a significant prognostic factor in
glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose of the …
glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose of the …
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating
vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently …
vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently …
